Core Viewpoint - Fosen Pharmaceutical's subsidiary has received approval from the National Medical Products Administration of China for the marketing application of Enzalutamide soft capsules, targeting specific types of prostate cancer [1] Company Summary - Fosen Pharmaceutical's subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., has developed Enzalutamide soft capsules [1] - The approved indications include treatment for high-risk non-metastatic castration-resistant prostate cancer (NM-CRPC) in adult patients and asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (CRPC) in adults who have not received chemotherapy after androgen deprivation therapy (ADT) failure [1] Industry Summary - Prostate cancer is the second most common malignancy among men globally and the fifth leading cause of cancer-related deaths [1] - The incidence of prostate cancer in China is lower than in Western countries but has been increasing in recent years [1] - Enzalutamide is an androgen receptor inhibitor that competes with androgens for binding to androgen receptors, inhibiting their nuclear translocation and interaction with DNA [1] - Enzalutamide has shown efficacy in inhibiting prostate cancer cell proliferation and inducing cell death in vitro, and it has reduced tumor volume in mouse models of prostate cancer [1] - Enzalutamide was first launched in the United States in 2012, followed by the European Union in 2013, and was approved for use in China in 2019 [1]
福森药业(01652.HK)"恩扎卢胺软胶囊"获批上市